These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
481 related articles for article (PubMed ID: 18676761)
1. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Wu JY; Wu SG; Yang CH; Gow CH; Chang YL; Yu CJ; Shih JY; Yang PC Clin Cancer Res; 2008 Aug; 14(15):4877-82. PubMed ID: 18676761 [TBL] [Abstract][Full Text] [Related]
2. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097 [TBL] [Abstract][Full Text] [Related]
3. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573 [TBL] [Abstract][Full Text] [Related]
5. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038 [TBL] [Abstract][Full Text] [Related]
6. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686 [TBL] [Abstract][Full Text] [Related]
7. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609 [TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039 [TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947 [TBL] [Abstract][Full Text] [Related]
10. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594 [TBL] [Abstract][Full Text] [Related]
11. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Sugio K; Uramoto H; Onitsuka T; Mizukami M; Ichiki Y; Sugaya M; Yasuda M; Takenoyama M; Oyama T; Hanagiri T; Yasumoto K Lung Cancer; 2009 Jun; 64(3):314-8. PubMed ID: 18992959 [TBL] [Abstract][Full Text] [Related]
12. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855 [TBL] [Abstract][Full Text] [Related]
13. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623 [TBL] [Abstract][Full Text] [Related]
14. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612 [TBL] [Abstract][Full Text] [Related]
16. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541 [TBL] [Abstract][Full Text] [Related]
18. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572 [TBL] [Abstract][Full Text] [Related]
19. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687 [TBL] [Abstract][Full Text] [Related]
20. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Riely GJ Lung Cancer; 2008 Jun; 60 Suppl 2():S19-22. PubMed ID: 18513580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]